We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
EntreMed, a clinical-stage pharmaceutical company developing therapeutics primarily
for the treatment of cancer and inflammatory diseases, today announced that
Duke University Medical Center has received a grant from the Susan G. Komen
Breast Cancer Foundation to study the company's lead compound, 2ME2 (2-Methoxyestradiol
or Panzem), in metastatic breast cancer. Basic, translational and clinical studies
will be conducted using Panzem NCD in combination with a variety of chemotherapeutic
agents to determine the effect of 2ME2 on chemotherapy resistant tumors. EntreMed
will supply Panzem NCD for these studies.
CiVentiChem, a provider of integrated chemistry services, announced today that
it has entered into a research and development collaboration with Tranzyme Pharma,
a leading biopharmaceutical company developing novel mechanism-based therapeutics
for the treatment of gastrointestinal disorders. Under the terms of the agreement,
CiVentiChem will provide research services in the areas of medicinal chemistry,
custom compound synthesis and process development.
Pingchuan Pharmaceutical has signed a purchase and sale agreement with Sinopharm
Medicine Holding Tianjin. Based on the agreement, Pingchuan authorizes Sinopharm
Tianjin to be its non-exclusive franchisee in the metropolitan area of Tianjin.
Xechem International has completed the sale of the majority of its interest
in CepTor Corporation in a transaction with CepTor that resulted in cash proceeds
to Xechem of $2.3 million. CepTor is a former Xechem corporate spin-off that
has been operating as an independent entity since February of this year following
the successful completion of its $12 million private equity offering.
Arrow Therapeutics announced a deal with Novartis, involving the development
and commercial sale of its small molecule inhibitor A60444 for the treatment
of respiratory syncytial virus.
Red tape in some African nations hardest hit by the AIDS pandemic is hampering
the efforts of Africa's biggest maker of generic medicines, Durban-based Aspen
Pharmacare, to secure orders for its generic AIDS drugs.
Growth in the Turkish pharmaceutical market has been hindered in recent years
by a combination of the country's poor economic climate, with a weak local currency
and high inflation, and stringent government sector regulations.